This month Xalkori (crizotinib) was approved by the U.S. Food and Drug Administration to treat advanced non-small-cell lung cancer (NSCLC) with tumors that have a rareROS1 gene mutation.
This is in addition to the drug’s approval (in 2011) for ALK positive advanced NSCLC.
At Asian Cancer Institute, we have ?renown international experts who have contributed to more than 10 global research publications to advances in treatment of Lung Cancer – some of these studies have even resulted in regulatory approval and are now recognized as landmark publications.
MD, DNB,FICP, PhD, ECMO, CPI, MBA
Medical Oncologist & Hematologist